
Oncology NEWS International
- Oncology NEWS International Vol 4 No 2
- Volume 4
- Issue 2
SoloPak Obtains Rights to Ganite
ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signed an agreement with Sloan-Kettering Institute for Cancer Research to acquire the exclusive worldwide rights to gallium nitrate (Ganite), which was FDA approved in 1991 for the treatment of acute hypercalcemia in cancer patients and had been manufactured by Fujisawa USA (Deerfield, Ill).
ELK GROVE VILLAGE, Ill--SoloPak Pharmaceuticals, Inc. has signedan agreement with Sloan-Kettering Institute for Cancer Researchto acquire the exclusive worldwide rights to gallium nitrate (Ganite),which was FDA approved in 1991 for the treatment of acute hypercalcemiain cancer patients and had been manufactured by Fujisawa USA (Deerfield,Ill).
The agreement involves a grant of SoloPak equity to the Instituteand a commitment of funds from SoloPak to complete clinical trials.
Over the next 2 to 3 years, SoloPak plans to seek approval ofgallium nitrate for the treatment of chronic hypercalcemia andbone metastases in cancer patients, and to launch clinical trialsof the agent in Paget's disease and osteoporosis.
Articles in this issue
almost 31 years ago
FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packagesalmost 31 years ago
Multidisciplinary Approach Urged For Pain Reliefalmost 31 years ago
FDA Approves New Indication for Neupogen: Chronic Neutropeniaalmost 31 years ago
Department of Labor Wants to Study Possible Occupation-Cancer Linksalmost 31 years ago
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLCalmost 31 years ago
ASH Panel: How Many Hemotologists/Oncologists Are Enough?almost 31 years ago
Mammography Van Brings Breast Cancer Screening to the Workplacealmost 31 years ago
FDA to Build $600 Million Campusalmost 31 years ago
Finasteride Studied as Prostate Ca PreventiveNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































